Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Aumolertinib + Cisplatin + Paclitaxel |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Aumolertinib | HS-10296||HS10296|Almonertinib | EGFR Inhibitor 3rd gen 26 | Aumolertinib (HS-10296) is a third-generation small molecule inhibitor of EGFR activating mutations and EGFR T790M (PMID: 28149837, PMID: 32895156). | |
Cisplatin | Platinol | CDDP | Chemotherapy - Platinum 7 | Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary). |
Paclitaxel | Taxol | 7-Epipaclitaxel | Antimicrotubule Agent 14 BCL2 Family Inhibitor 6 | Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05493501 | Phase III | Aumolertinib + Cisplatin + Pemetrexed Disodium Aumolertinib + Carboplatin + Pemetrexed Disodium Aumolertinib + Carboplatin + Paclitaxel Aumolertinib + Cisplatin + Paclitaxel Aumolertinib + Cisplatin + Nab-paclitaxel Aumolertinib + Carboplatin + Nab-paclitaxel Aumolertinib + Cisplatin + Gemcitabine Aumolertinib Aumolertinib + Carboplatin + Gemcitabine Osimertinib | Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer | Terminated | USA | 0 |